长江生命科技(0775.HK)今日复牌高开,盘初一度飙升41.67%至0.68港元,股价创2023年11月以来新高。消息面上,公司宣布 ,其针对滋养层细胞表面抗原2(TROP2)的新型癌症疫苗在临床前阶段实验室测试中取得良好的早期成果。
公司认为TROP2是一种令人振奋的治疗性标靶癌症疫苗,在小鼠研究中观察所见,公司的TROP2癌症疫苗展现前所未见的成功抗癌效能。公司期望TROP2癌症疫苗能迅速进展至临床研究阶段,以尽早带来肿瘤治疗新方向,并造福病患。本公告刊发日期前,公司已向香港知识产权署提交circRNA及融合蛋白TROP2癌症疫苗的原授标准专利申请,并向美国专利商标局提交相关临时专利申请。经过详细评估,公司认为该TROP2癌症疫苗的成功商品化可为公司带来潜在的重大经济效益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.